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Bromodomain-containing protein 4 (BRD4) is an epigenetic reader and oncology drug target
that regulates gene transcription through binding to acetylated chromatin via bromodomains.
Phosphorylation by casein kinase II (CK2) regulates BRD4 function, is necessary for active
transcription and is involved in resistance to BRD4 drug inhibition in triple-negative breast
cancer. Here, we provide the first biophysical analysis of BRD4 phospho-regulation. Using
integrative structural biology, we show that phosphorylation by CK2 modulates the dimer-
ization of human BRD4. We identify two conserved regions, a coiled-coil motif and the Basic-
residue enriched Interaction Domain (BID), essential for the BRD4 structural rearrangement,
which we term the phosphorylation-dependent dimerization domain (PDD). Finally, we
demonstrate that bivalent inhibitors induce a conformational change within BRD4 dimers
in vitro and in cancer cells. Our results enable the proposal of a model for BRD4 activation
critical for the characterization of its protein-protein interaction network and for the devel-
opment of more specific therapeutics.
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BRD4 (BRomoDomain protein 4) is an epigenetic readerbelonging to the BET (Bromodomain and Extra-Terminaldomain) protein family, which also includes BRD2, BRD3,
and BRDT (BRomoDomain protein Testes-specific)1. BRD4 has
key functions in multiple processes including transcriptional
regulation1, DNA damage response2, and virus maintenance and
replication3. At the basis of most BRD4 functions is the ability to
bind to acetylated chromatin through bromodomain 1 (BD1) and
bromodomain 2 (BD2) that are located in tandem within the
N-terminal part of the protein. These are highly conserved 110
amino acid (aa) domains composed of a bundle of four helices
separated by two loops that form a hydrophobic pocket for
interaction with mono- or di-acetylated peptides4. Despite the
high sequence identity between the two bromodomains, they
recognize different epigenetic marks: BD1 binds in vitro to mono-
and multiply-acetylated H4 peptides, while BD2 exhibits pro-
miscuous interaction with both acetylated H3 and H4 histone
tails4 and it can also bind to acetylated transcription factors, such
as TWIST15. All members of the BET family also contain an
extra-terminal domain (ET), which in BRD4 has been demon-
strated to interact with multiple binding partners and influence
gene transcription6. Finally, the long isoforms of BRD4 and
BRDT display an intrinsically disordered region, shown to form
in BRD4 phase-separated droplets at the chromatin to compart-
mentalize transcription7, and a conserved C-Terminal Motif that,
together with BD2, contributes to activate transcription of tar-
geted genes by recruiting the positive transcriptional elongation
factor b8,9. It has been recently reported that the BRD4 isoform C
(aa 1-722), which lacks the long C-terminal intrinsically dis-
ordered region and has the last three residues ETA substituted by
GPA, is also able to form liquid-like condensates at the nucleus,
similarly to the long isoform A (aa 1–1362). The two isoforms
seem to modulate the expression of a subset of genes in an
opposite fashion10,11 and have been demonstrated to locate to
distinct nuclear compartments12.
The discovery that the transcription of c-MYC and other
oncogenic genes is regulated by BRD413 and that selective inhi-
bition of BET bromodomains with small molecules, JQ1 and I-
BET, is effective against various hematological cancers14–18,
encouraged further development of BET inhibitors towards the
clinic. BET inhibitors act by binding to the acetylated lysine
binding pockets of BD1 and BD2 and disrupting interactions with
chromatin and transcription factors, thus suppressing transcrip-
tion of c-MYC and other proto-oncogenes. Although the majority
of BET inhibitors bind to both BD1 and BD2, specific compounds
targeting either BD1 or BD2 of BET proteins were recently
developed19,20. Importantly, the efficacy of some of the BET
inhibitors against hematological and solid tumors has been
demonstrated in pre-clinical studies21, and they are also of
interest in inflammatory and viral diseases. Although the inhi-
bition of BRD4 is likely to be the main target of BET inhibitors, it
has to be stressed that these small-molecules bind to all members
of the BET protein family and that specific inhibitor of each
member has been difficult to identify. Recently, several bivalent
BET inhibitors (biBETs) were developed by three distinct groups,
which are able to target two bromodomains (BD1 or BD2)
simultaneously and show higher potencies and efficacies com-
pared to monovalent counterparts22–25.
Despite the broad therapeutic interest, the molecular details of
BRD4 function and regulation are not fully understood. Phos-
phorylation of BRD4 by casein kinase 2 (CK2) is necessary for
active gene transcription and controls the activity of BRD4 by
positively regulating its binding to acetylated chromatin, as well
as to human p53 and viral E2 transcription factors26,27. In
addition, hyperphosphorylation of BRD4 has been identified as a
resistance mechanism in triple-negative breast cancer against BET
inhibition due to an increased p-BRD4-mediated recruitment of
the Mediator complex, a multi-protein activator of RNA pol II28.
As in many targets of CK2, BRD4 harbors multiple highly con-
served consensus sites for CK2 phosphorylation (S/TxxE/D,
where x is any residue) that are located in two main clusters: one,
named N-terminal phosphorylation sites (NPS) downstream of
BD2, and another, C-terminal phosphorylation sites (CPS), after
the ET domain. A proposed phospho-regulation mechanism
involves a conformational switch driven by the NPS29. It was
suggested that the unphosphorylated NPS interacts with BD2 to
inhibit chromatin binding. Upon phosphorylation by CK2, NPS
was proposed to bind to a lysine-rich region immediately
downstream, called BID (Basic-residue enriched Interaction
Domain), thereby releasing auto-inhibition of BD2 and allowing
chromatin interaction. Although the “phospho-switch” is an
elegant and simple model for the regulation of BRD4 activity,
there are currently no structural or biophysical reports in its
support.
Here, we provide insights into the phospho-regulation of
human BRD4. Using an integrative structural biology approach,
we demonstrate that BRD4 dimerizes upon phosphorylation of
NPS by CK2. We identify BID and a conserved coiled-coil region
downstream of the bromodomains as required for dimerization.
Finally, we show the effects of biBETs on the BRD4 conformation
in vitro and in cellular NanoBRET assays. Guided by our ana-
lyses, we propose a revised model for the regulation of BRD4 in
which phosphorylation modulates the conformation and oligo-
meric state of the protein, thus creating a multi-valent platform
for co-localization of transcriptional complexes. This work not
only provides a key for the interpretation of phospho-regulated
protein-protein interactions of BRD4, but it also gives mechan-
istic insight into the control of BRD4 activity while underlining
the importance of biophysical and structural data on physiolo-
gically relevant constructs in the understanding of protein func-
tional mechanisms.
Results
Dimerization of BRD4 is driven by phosphorylation and
requires the BID region. To dissect the effects of phosphoryla-
tion on the structure of BRD4, we used three previously described
constructs29: 1) BRD41–530, encompassing BD1, BD2, and NPS;
2) BRD41–579, which further includes BID; 3) BRD41–722, which
additionally spans the ET domain and the CPS region, and
comprises the isoform C (Fig. 1a). Attempts to obtain protein
samples of isoform A (aa 1–1362), failed due to low expression
levels in insect cells and proteolytic instability.
Unphosphorylated proteins were produced by expression in E.
coli, while phosphorylated samples were generated by expression
in insect cells or by in vitro CK2-mediated phosphorylation.
Purified proteins were obtained from both bacteria and insect
cells (Fig. 1b) and multiply phosphorylated sites were observed by
mass spectrometry from insect cells and in vitro phosphorylated
samples (Supplementary Fig. 1 and 2). A single acetylation site
was also identified in purified proteins produced from insect cells,
but not in proteins from E. coli. Although BRD4 has been
reported to be an atypical protein kinase with auto-
phosphorylation activity30, we did not observe any phospho-
adducts in the bacterial samples by mass spectrometry and we did
not detect any auto-phosphorylation of BRD4 by ADPglo assay in
the presence of ATP (Supplementary Fig. 3).
Analysis by analytical size-exclusion chromatography (SEC)
revealed differences in elution profiles that were construct and
phosphorylation dependent: while phosphorylated BRD41–530
eluted later than the unphosphorylated form, indicating protein
compaction, the peaks of both phosphorylated BRD41–579 and
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BRD41–722 shifted toward earlier elution volumes, suggesting a
phosphorylation-dependent oligomerization or structural elonga-
tion (Fig. 1c). Interestingly, the addition of high salt abrogated the
effects of phosphorylation on BRD41–530 but only had a partial
effect on BRD41–579 and no effect on BRD41–722. Since ionic
strength is known to modulate electrostatic interactions, these
seem to predominantly drive the conformational compaction of
BRD41–530, while for the BRD41–579 and BRD41–722 structural
changes, the electrostatic contributions are less sensitive to salt
concentration and suggest that these interactions are stronger and
may also involve additional hydrophobic contacts.
To further investigate the oligomeric state of the BRD4
constructs, size-exclusion chromatography multi-angle light-
scattering (SEC-MALS), and analytical ultracentrifugation
(AUC) sedimentation velocity and equilibrium experiments were
undertaken (Fig. 1d and Table 1). First, in agreement with the
Fig. 1 Dimerization of BRD4 constructs containing BID upon CK2 phosphorylation. a Summary of the BRD4 constructs used in the study. A schematic
representation of full-length BRD4 (long isoform A) and known regions is reported. b Coomassie-stained SDS-PAGE gel showing the purity of the
recombinantly produced BRD4 constructs 1-530, 1-579, 1-722. c Elution profiles of analytical size-exclusion chromatography (SEC) performed with 20 µM
of the indicated constructs in the presence of 250mM NaCl or 1 M NaCl. Std: Gel filtration standards (Bio-Rad) analysed in the corresponding low or high
salt running buffer. d Elution profiles of the indicated constructs analysed by SEC-MALS. Samples are labeled as follows: black line indicates purified from
bacteria, blue line indicates purified from insect cells, orange line indicates phosphorylated in vitro using CK2, dotted grey line in panels c, and d indicate
protein molecular weight standards. The dotted line at each peak, colored as above, indicates the measured MW. The dotted horizontal grey lines in panel
d represent the theoretical MW of the monomer or dimer of BRD41–530, BRD41–579, BRD41–722, calculated from the primary sequence.
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earlier SEC experiments, both phosphorylated and unphosphory-
lated BRD41–530 were monomeric, and the frictional coefficient
(f/f0) and sedimentation coefficient both indicated that the
phosphorylation resulted in a more compact form of the protein.
Second, BRD41–579 and BRD41–722 samples were dimeric when
phosphorylated and monomeric when unphosphorylated. Ana-
lysis of the frictional ratios and sedimentation coefficients also
revealed interesting differences in the conformation of dimeric
BRD41–579 and BRD41–722. The BRD41–722 dimer adopted a
more compact conformation than the truncated BRD41–579
dimer, suggesting that the region comprising residues 580-722
mediates interactions that stabilize the compact conformation of
BRD41–722. The presence of the acetylation in the insect cell
construct did not seem to affect the structure of the protein, as
indicated by the similar behavior of CK2 in vitro phosphorylated
proteins and insect cell samples.
Overall, this analysis suggests that phosphorylation by CK2
induces a dimerization of BRD4 isoform C that is mediated by
electrostatic and hydrophobic effects and is dependent upon the
presence of the positively charged region BID.
Motif B is involved in the phospho-driven structural change of
BRD4. To gain insight into the structural rearrangements that
occur upon phosphorylation, we compared the unphosphorylated
and in vitro phosphorylated BRD4 constructs by Hydrogen-
Deuterium eXchange Mass Spectrometry (HDX-MS). For all
constructs, we identified a high number of unique peptides,
common between the two phosphorylated states, which provided
good coverage of BD1, BD2 (≥92%), and ET domains (74.7%)
(Supplementary Fig. 4). Coverage of some parts of the BD1-BD2
linker and the BID region was not obtained, most probably due to
the hydrophobic or highly positively charged primary sequences.
Peptides derived from the NPS and CPS regions were excluded
from the analysis, as these were differentially modified in the
phosphorylated and unphosphorylated forms.
The largest change in deuterium incorporation was found in 6
overlapping peptides in BRD41–579 and in BRD41–722 spanning
the region between the NPS and BID (aa 506-527) (Fig. 2a, b and
Supplementary Fig. 4). Notably, these peptides exhibit reduced
HDX in the phosphorylated proteins compared to the unpho-
sphorylated counterparts, but this only occurred in BRD41–579
and BRD41–722, the two constructs that dimerize upon phos-
phorylation. In contrast, there was no change in deuterium
uptake in the corresponding residues of BRD41–530. The 506-527
region contains three heptad repeats, a characteristic of coiled-
coil structures (Fig. 2c). Analysis of the BRD4 sequence using the
LOGICOIL coiled-coil prediction algorithm31, strongly predicts a
coiled-coil structure involving residues 506-527 with an anti-
parallel dimer configuration (Supplementary Fig. 5). Moreover,
residues 506-527 are part of a region, named “motif B”, conserved
among BET proteins (Fig. 2c) that has been proposed to mediate
dimerization of BRD2 and other BET proteins, based on yeast
2-hybrid and co-immunoprecipitation data32.
Minor reductions in HDX were also observed in three other
regions of phosphorylated BRD41–722: aa 65–71 of the helix Z of
BD1, aa 184–190 of the linker region immediately downstream of
BD1, aa 362–386, which are part of the helix Z and the ZA-loop
of BD2, and aa 621–644 and 657–675, which comprise most of
the ET domain (Fig. 2a and Supplementary Fig. 6).
All of the HDX changes described above exhibit EX2 kinetics,
which occur when the rate of protein refolding from a
temporarily unfolded state is much faster than the rate of HDX,
resulting in a gradual exchange of hydrogen. On the other hand, if
the rate of protein refolding is slower than the rate of HDX, some
residues will exchange before the protein returns to the folded
state. In the HDX-MS analysis of all protein batches of BRD41–530
and BRD41–722, we identified peptides from the BD2 domain that
displayed EX1 kinetics. This was not observed in the phosphory-
lated forms or in BRD41–579 (Supplementary Fig. 7). The
presence of EX1 kinetics suggests that BD2 has a more plastic
structure than BD1, and that BD2 may be stabilized in the context
Table 1 Summary of the SEC-MALS and AUC sedimentation velocity and equilibrium experiments.










1-530 unphos. (bacteria) 60,512.7 81,330 62,883 2.58 2.35 64,200
insect 60,569.7 86,970 68,124 3.18 2.10 79,500
CK2 phos. 60,512.7 79,600 65,609 3.10 1.73 59,500
1-579 unphos. (bacteria) 66,376.5 87,130 80,511 3.13 1.97 86,100
insect 66,433.5 129,500 91,765 4.42 2.40 152,000
CK2 phos. 66,376.5 131,510 113,385 4.35 2.19 142,000
1-722 unphos. (bacteria) 82,415.3 96,170 117,258 3.53 1.72 78,200
insect 82,472.3 147,200 145,923 5.65 1.58 123,000
CK2 phos. 82,415.3 156,800 131,824 5.41 1.56 112,000
7A CK2 phos. 82,303.3 105,200 – – – –
6A CK2 phos. 82,319.3 134,600 – – – –
Δ506-530 insect 80,404.9 91,200 – 3.71 1.76 80000
Δ506-530 λ-
phosphatase
80,404.9 81,750 – 2.95 2.41 82700
1-722 λ-
phosphatase
+ iBET 82,472.3 88,157 – – – –
+ AZD5153 82,472.3 84,003 – – – –
+ 10 82,472.3 83,858 – – – –
+ 6 82,472.3 84,747 – – – –
+ 7 82,472.3 86,097 – – – –
1-722 insect + iBET 80,404.9 120,321 – – – –
+ AZD5153 80,404.9 111,703 – – – –
+ 10 80,404.9 114,276 – – – –
+ 6 80,404.9 112,726 – – – –
+ 7 80,404.9 117,168 – – – –
*f/f0= frictional coefficient.
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of the BRD41–579 construct or by the phosphorylation-driven
conformational rearrangement of BRD41–530 and BRD41–722.
Phosphorylation of BRD4 brings BD, BID, and ET regions in
proximity. To gain further insight into the architecture of the
BRD4 dimer, we performed chemical crosslinking followed by
MS (XL-MS) of the most relevant physiological form, BRD41–722.
When preparing cross-linked samples, a distinct slower-migrating
band with a MW consistent with a dimer (165 kDa) appeared in
both unphosphorylated and CK2 in vitro phosphorylated
BRD41–722 samples at increasing concentrations of cross-linker
(Supplementary Fig. 8). The accumulation of the dimeric band
was clearly more marked in the phosphorylated sample. This is
consistent with BRD41–722 having a propensity to form a dimer
via the coiled-coil motif B that is stabilized only upon phos-
phorylation, thus resulting in the dimer being the main species
present in solution for phosphorylated BRD41–722. The unpho-
sphorylated monomer and the phosphorylated dimeric species
were purified by SEC prior to the analysis of the cross-linked
peptides. In total, 69 putative intra-molecular cross-links and 104
inter-molecular cross-links were found, unique to the monomer
or dimer, respectively (Fig. 3). These were mainly within or in the
proximity of the BD1, BD2, BID, and ET regions, which suggests
Fig. 2 Change in Hydrogen-Deuterium exchange of motif B upon BRD4 dimerization. a Average difference of deuterium uptake for each residue of the
indicated constructs (BRD41–530, BRD41–579, and BRD1–722) between the unphosphorylated sample (unphos.) and the sample subjected to CK2
phosphorylation (CK2 phos.) or purified from insect cell (insect). A positive differential uptake indicates a higher deuterium uptake (more exposed region)
in the unphosphorylated sample and a protected region in the phosphorylated sample. Only peptides with changes above 0.5 Da and greater than 2.3x SD
were taken into account. Areas with no coverage are represented as gaps. The protection upon phosphorylation of motif B observed in BRD41–579 and
BRD41–722, but not in BRD41–530, is highlighted with a rectangle. In these graphs, regions showing EX1 kinetics are considered with no difference. For details
on the calculation, see the Materials and Methods section. Orange lines indicate the difference in deuterium update between unphosphorylated BRD4
1-722 and BRD4 1-722 phosphorylated by CK2 in vitro. Blue lines indicate the difference in deuterium update between unphosphorylated BRD41–722 and
insect cell-expressed BRD41–722, b Example of a peptide in the region spanning aa 506-527 showing notable deuterium uptake differences over the
shortest exposure time (3 sec on ice) upon CK2 phosphorylation in BRD41–579 and BRD41–722, but not in BRD41–530. The relative deuterium uptake (Da)
over deuterium exposure time is reported for each n= 3 independent experiments. Orange lines indicate CK2 phosphorylated samples and grey lines
indicate unphosphorylated samples. c Sequence alignment of human BET proteins and BRD4 proteins from various species performed with ClustalOmega
and represented with ClustalW color scheme. H.s.: Homo sapiens;M.m.:Mus musculus; E.c.: Equus Caballus; B.t.: Bos taurus; X.l.: Xenopus laevis; D.r.: Danio rerio;
S.c.: Saccharomyces cerevisiae. The conserved NPS region with consensus CK2 phosphorylation sites (S/TxxE/D, where x is any residue) and Motif B are
indicated. The JPred secondary structure prediction is reported below the sequences where residues predicted to be in a coiled coil are indicated below by
‘C’. Arrows point towards the conserved hydrophobic residues within the coiled-coil region that are predicted to form the inner hydrophobic interaction
surface.
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extensive cross-talk between the domains in the monomer that is
increased after CK2 phosphorylation. Many putative inter-
molecular cross-links were found between the C-terminal part
of one molecule (BID and ET domain) and the N-terminus of the
other molecule (BD1 and residues immediately downstream of
it), suggesting a possible antiparallel arrangement of the
BRD41–722 dimer, in line with the LOGICOIL prediction of the
coiled-coil oligomeric state (Supplementary Fig. 5). Interestingly,
we found a putative inter-BRD41–722 cross-link between the same
lysine 519, located in the middle of the predicted coiled coil of
motif B.
In general, we observed an agreement between the regions
involved in putative inter-molecular cross-links and those with
reduced deuterium uptake upon CK2 phosphorylation of
BRD41–722 in the HDX-MS analysis (Fig. 2a and Fig. 3).
Aa 506-530 of motif B and the phosphorylation of NPS are
required for BRD4 dimerization. Next, we sought to dissect the
contribution of the two CK2 phosphorylated regions, NPS and
CPS, to the structural rearrangement of BRD41–722. To this end,
we produced two mutant constructs containing serine-to-alanine
mutations of all CK2 consensus sites in the NPS region
(BRD41–722 7A) or in the CPS region (BRD41–722 6A) (Fig. 4a).
After incubation with CK2, the expected reduction in phos-
phorylation of both the mutants relative to wild type was con-
firmed by mass spectrometry (Supplementary Fig. 1). Analysis by
SEC-MALS revealed that the BRD41–722 6A mutant still displayed
an apparent molecular weight similar to that of the wild-type
protein and consistent with a dimer, while the behavior of the
BRD41–722 7A mutant was consistent with monomers indicating
that the CK2 sites of the NPS region, but not of CPS, are critical
for phospho-dependent modulation of oligomeric state (Fig. 4b
and Table 1). Moreover, comparison of the HDX uptake of the
mutants to the wild-type protein, showed that the biggest dif-
ference was within motif B (aa 514–527), where HDX was lower
in the BRD41–722 7A mutant, but unchanged in the BRD41–722
6A mutant (Fig. 4c, d). The minor HDX changes observed in BD1
and BD2, aa 184–190, and the ET domain may be due to phos-
phorylation of residues other than the consensus CK2 sites in the
NPS and CPS. Taken together, these results indicate that phos-
phorylation of the NPS is required for the formation of the
BRD41–722 dimer. (Fig. 2a).
To test the role of motif B in the phospho-driven dimerization
of BRD41–722 we then produced mutant constructs in which
residues 506-530 of BRD41–722 were deleted and replaced with a
12-aa glycine-serine rich flexible linker (Fig. 4e). E. coli expression
of BRD41–722(Δ506-530) was greatly reduced suggesting that
deletion of the coiled-coil region impacted protein stability;
however, insect cell expression enabled purification of the
samples. We then generated the unphosphorylated protein by
incubating the insect cell BRD41–722(Δ506–530) with λ-
phosphatase. Mass spectrometry confirmed a substantial reduc-
tion in phosphorylation levels (Supplementary Fig. 9). Compar-
ison of the oligomerization state of the phosphorylated and λ-
phosphatase-treated BRD41–722(Δ506–530) by SEC-MALS and
AUC revealed that both the samples were present in monomeric
state in solution (Fig. 4f, Table 1). Interestingly, the analysis of the
frictional and sedimentation coefficients indicates a large
conformational difference between the two samples, suggesting
a more compact shape of BRD41–722(Δ506-530) when phos-
phorylated (Table 1). This molecular rearrangement resembles
the one observed for the BRD41–722 dimer and indicates that
phosphorylation is triggering a molecular compaction regardless
of the change in oligomerization.
In summary, the Δ506–530 mutant protein analysis confirms
that motif B is required for BRD4 dimerization and that the
formation of the coil-coiled interface is essential for the stability
of the BRD41–722 dimer.
BRD4 dimerization is detected in HCT116 cells by NanoBRET.
The results of the in vitro biophysical analysis prompted us to test
BRD4 dimerization in human cancer cells. We performed bio-
luminescence resonance energy transfer (NanoBRET) in HCT116
cells by transiently expressing two constructs of BRD41–722 fused
to either a Nanoluciferase tag (NanoLuc, donor) or a Halo-tag
(acceptor) (Fig. 5a). A NanoBRET signal was observed in the
presence of the BRD41–722 NanoBRET pair (Fig. 5b, c), in con-
trast to control (Halo-tag only and NanoLuc-BRD41–722) indi-
cating that dimerization of BRD41–722 occurs in this cellular
context. It is worth to note that a higher NanoBRET signal was
observed when the NanoLuciferase and the Halo-tag were added
at the N-ter and C-ter of the molecules, respectively, consistent
with an antiparallel arrangement of the dimer. The specificity of
BRD41–722 dimerization was confirmed in a saturation binding
experiment with increasing concentrations of acceptor expression
plasmid DNA (Fig. 5d), and in a competition experiment, in
which untagged BRD41–722 expression plasmid DNA was titrated
against a constant amount of BRD41–722 acceptor/donor pair
plasmid DNA, leading to a reduction of the NanoBRET signal
(Fig. 5e).
These results support the biophysical driven hypothesis that
BRD4 dimerizes in cells.
Effects of the binding of bivalent BET inhibitors to BRD4
conformation. We recently described a series of highly potent
biBETs that simultaneously bind tandem bromodomains23,33
(Supplementary Fig. 10). These compounds were found to effi-
ciently displace both BRD4 isoform A (1–1362) (FL) and isoform
C (1–722) from histone H3 in NanoBRET assays with a much
lower IC50 than the monovalent I-BET (Fig. 6a). We asked
whether modulation of BRD4 oligomeric state might be relevant
in the mechanism by which biBETs achieve exceptional potency
in cell assays. Using our NanoBRET assay, we observed a
concentration-dependent increase in BRD41–722 BRET signal
after addition of bivalent compounds, which was not detected
with the monovalent I-BET (Fig. 6b), reflecting either an increase
in oligomerization or a conformational change that brings the
Fig. 3 XL-MS analysis provides insight into the overall topology of the
BRD4 dimer. Graphical representation of the cross-link (XL)-MS analysis.
Cross-links found only in the CK2 phosphorylated sample (green) or only in
the unphosphorylated sample (purple) are represented as inter-molecular
cross-links or intra-molecular cross-links, respectively. The regions showing
a reduced deuterium uptake upon phosphorylation in the HDX-MS
experiment are highlighted with pale yellow: aa 65–71, 184–190, 362–386,
506–527, 621–644, 657–675.
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NanoBRET donor and acceptor into closer proximity. Interest-
ingly, for all but one of the bivalent compounds, the EC50 is >10-
fold higher than the IC50 required to inhibit BRD41-722-H3
binding. AZD5153 is the exception, which may suggest a different
mode of inhibition relative to the other bivalent compounds. In
order to differentiate between an increased oligomerization or a
conformational change induced by iBETs, we performed SEC-
MALS experiments on BRD41–722 in the presence of compounds
(Fig. 6c, d). We tested both the insect cell-expressed BRD41–722,
and its dephosphorylated monomeric form. Although SEC-MALS
indicates a mixed population of dimer and monomer BRD41–722
before dephosphorylation, all biBETs shift the BRD4 peak to a
faster migrating population without change in molecular weight,
whereas I-BET failed to shift the peak. The same was observed for
the dephosphorylated BRD4 monomer. Our results indicate that
biBETs induce conformational compaction in BRD4 with no
effect on oligomeric state. This is consistent with previously
observed biBET induced compaction of BRD444–460 (BD1-BD2
tandem domain) in SAXS and AUC studies23.
These data suggest that biBETs employ the same binding mode
toward monomeric and dimeric BRD4 and confirm that the
conformational compaction of BRD4 is relevant to the mechan-
ism of biBETs inhibition.
Discussion
In this study, we provide a comprehensive biophysical and
structural analysis of a series of constructs of human BRD4,
including BRD41–722, which represents the isoform C. Using
SEC-MALS and AUC, we observed that BRD41–579 and
BRD41–722, but not BRD41–530, which lacks the BID domain,
Fig. 4 Biophysical analysis of the regions and the phosphorylation sites required for BRD4 dimerization. a Schematic overview of the BRD41–722
phospho-deficient mutants 7A and 6A. In the wild-type (WT) sequence of NPS and CPS, the CK2 consensus sites are highlighted in bold. In the 7A and 6A
mutant sequences, the serine residues mutated to alanine are highlighted in red. b SEC-MALS elution profiles for the BRD41–722 constructs, produced in E.
coli and phosphorylated by CK2. The grey line indicates WT, red line indicates the 7A mutant, and yellow line the 6A mutant. The dotted lines at each peak,
colored as above, indicate the experimentally calculated MW. The dotted horizontal black lines represents the theoretical MW of the monomer or dimer of
BRD41–722, calculated from the wild-type primary sequence. c Difference of deuterium uptake for each residue between the WT and the 7A (in red) or 6A
(in yellow) mutants. All samples have been produced in bacteria and phosphorylated by CK2. A negative differential uptake indicates a lower deuterium
uptake (more protected region) in the wild-type sample. Only peptides with changes above 0.5 Da and greater than 2.3x SD were taken into account. The
increased exposure of motif B in the 7A mutant is highlighted with a rectangle with dotted line. Areas with no coverage are represented as gaps. For details
on the calculation, see the Materials and Methods section. d Example of the relative deuterium uptake of a peptide within motif B. The uptake is
substantially reduced in the shortest exposure time (3 sec on ice) in the phosphorylated BRD41–722 7A mutant compared to the phosphorylated wild type.
The relative deuterium uptake (Da) over deuterium exposure time is reported for each n= 3 independent experiments. Grey circles and line indicates WT,
red circle and line 7A mutant, yellow circle and line 6A mutant. e Schematic representation of the BRD41–722 Δ506-530 produced in insect cells. In the
wild-type (WT) sequence, the region spanning residues 506–530 is in bold. In the Δ506–530 mutant sequence, the 12-residue glycine-serine-rich flexible
linker used to replace the 506-530 aa sequence is highlighted in red. f SEC–MALS elution profiles of the BRD41–722 Δ506–530 produced in insect cells and
treated (blue line) or not treated (light blue line) with λ-phosphatase. The dotted line at each peak, colored as above, indicates the experimentally
calculated MW. The dotted horizontal lines represent the theoretical MW of the monomer or dimer of BRD41-722Δ506–530.
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dimerize after phosphorylation by CK2. Dimerization of
BRD41–722 was also observed in mammalian cancer cells using
NanoBRET assays. Based on the increased protection identified
by HDX-MS, and on our mutation studies, we demonstrated that
BRD41–722 dimerization requires a coiled-coil region (aa 506-530)
within motif B, BID, and phosphorylation of NPS. We propose a
model for the phosphorylation-driven conformational change of
BRD4 (Fig. 6e). In this model, unphosphorylated BRD4 is a
monomer; however, upon phosphorylation by CK2, BRD4 forms
a stable homodimer through an interface comprising the phos-
phorylated NPS, coiled-coil motif B and BID. Guided by I) the
overall topology of the dimer obtained by XL-MS, II) the coiled-
coil oligomeric state prediction by LOGICOIL and III) the pre-
vious observation with isolated domains that phosphorylated NPS
binds to BID29, we propose a head to tail conformation of the
dimer. In this conformation, the negatively charged phosphory-
lated NPS of one monomer contacts the positively charged BID of
the other monomer, thus stabilizing the coiled-coil interaction.
Although our data are based on the analysis of the BRD4 isoform
C, the same phospho-regulated dimerization can be envisioned
also for the long isoform A, which shares the same residues,
including the regions forming the dimer interface. The biophy-
sical and structural analysis of phosphorylated BRD41–722 also
suggests a compact shape for the dimer in which the bromodo-
mains and the ET domain are in proximity to each other. This
configuration would therefore create a multi-valent platform that
brings protein ligands of BD2 and ET to the chromatin. Addi-
tional structural studies employing cryo-EM analysis of BRD4 in
complex with binding partners and chromatin will be necessary
to confirm this hypothesis.
The conformational phospho-switch model of BRD4 proposed
by Wu et al.1 is based on an autoinhibitory activity of NPS toward
BD1 and BD2, released by its phosphorylation and intra-
molecular interaction with BID29. In our HDX-MS analysis, we
did not observe an increase of HDX in BD1 or BD2 upon
phosphorylation, as would be expected from the phospho-switch
model due to release of autoinhibitory interactions. On the
contrary, we observed a small HDX reduction in several peptides
of BD1 and BD2, but only in BRD41–722. Interestingly, the pep-
tides of BD2 with reduced HDX are located in the ZA-loop and
involve the WPF (W374 P375 F376) shelf important for creating
the hydrophobic pocket hosting the acetylated lysines (Supple-
mentary Fig. 6). The intra-molecular interactions, established
upon BRD41–722 phosphorylation and dimerization, may there-
fore stabilize BD2 for binding to chromatin, positive transcrip-
tional elongation factor b or transcription factors. This hypothesis
is further supported by the EX1 kinetics of HDX observed in
BD2, which suggests an inherent plasticity of this specific bro-
modomain, with greater propensity to unfold in the
unphosphorylated state.
Using phospho-deficient mutants in either NPS (7A mutant)
or CPS (6A mutant), we identified NPS as a regulator of BRD4
dimerization. We did not observe any effect of phosphorylation of
CPS on BRD4 structure in our biophysical analyses (Fig. 4),
however this does not rule out a role for CPS in modulating
interactions with other co-regulatory proteins. We have therefore
identified a phosphorylation-dependent dimerization domain
(PDD) in BRD4, spanning residues 484–579 and comprising
NPS, coiled-coil motif B, and BID regions (Fig. 6e).
The coiled-coil interface of the BRD4 dimer is located within
motif B, a region that was shown to be required for BRD2-
chromatin binding in mitosis and was proposed to be a universal
dimerization motif in BET proteins32. Our structural, biophysical
and cellular analysis on BRD4 not only supports this hypothesis
but also shows that dimerization is modulated by CK2-mediated
phosphorylation of NPS and suggests a dynamic equilibrium
between monomer and dimer. The NPS region of BRD2 has an
insertion of around 13 negatively charged residues relative to
Fig. 5 NanoBRET analysis of BRD4 dimerization in cells. a Schematic summary of the NanoBRET assays to test BRD4 homo-dimerization in HCT116 cells.
The curved black arrow represents Bioluminescence Resonance Energy Transfer (BRET) between the Nanoluciferase donor (blue circle) and the Halo-tag
acceptor ligand (orange circle). b Overview of the NanoBRET transfected constructs used in the NanoBRET experiments, with BRD41–722 tagged at the
N-terminus with Nanoluciferase, and at the N-terminus or at the C-terminus with Halo-tag. c NanoBRET signal observed using NanoLuc-BRD41–722 and
Halo-BRD41–722 (dark grey bar) or NanoLuc-BRD41–722 and BRD41–722-Halo (grey bar). The single measurements and the mean with SD are reported
(n= 8 for samples and n= 4 for control independent experiments). d Titration NanoBRET experiments where increasing amounts of acceptor DNA
(BRD41–722-Halo) were transfected with a fixed amount of donor DNA (NanoLuc-BRD41–722). The mean with the standard error of the mean (SEM) is
reported (n= 4 independent experiments) e Competition NanoBRET experiments where increasing amount of untagged BRD41–722 DNA were transfected
with a fixed amount of donor and acceptor DNA pair (NanoLuc-BRD41–722 and BRD41–722-Halo). The reduction of the NanoBRET signal at increasing values
of untagged/Halo-tagged BRD41–722 ratio indicates a specific competition of the untagged protein towards BRD41–722-Halo for binding to NanoLuc-
BRD41–722. The mean with SEM is reported (n= 4 independent experiments).
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BRD4 and fewer CK2 consensus phosphorylation sites, perhaps
suggesting that BRD2 dimerization may not require phosphor-
ylation. Our AUC data also demonstrate that the isolated BRD4
bromodomains are monomeric, whereas BRD2 BD1 has been
shown to form stable dimers34, indicating differences in the
nature or affinity of the dimer contacts in BRD4 and BRD2.
It is interesting to note that many reported BRD4 binding
partners are oligomers: p53 (tetramer) binding to BID29; viral
latency-associated nuclear antigens kLANA and mLANA (both
the dimers and higher oligomers) binding to ET35,36; histone H3
and H4 (two copies of which are included in the octameric
nucleosome), binding to BD1 and BD2. Dimerization of BRD4,
and the resulting spatial proximity of four bromodomains, two
ET domains, and two BIDs, could therefore lead to the right
architecture not only for binding to multiple acetylated histone
tails of the same or adjacent nucleosome, but also for the efficient
recruitment of the other interacting oligomers.
The BRD4 isoform C forms liquid-like phase separations
(LLPS) at the nucleus involved in active gene transcription37
similar to those previously reported for the long isoform A. LLPS
and DNA binding was inhibited by phosphorylation via CK2 and
LLPS were also inhibited by the addition of a bivalent inhibitor,
but not by JQ1. Phosphorylation of BRD4 therefore promotes
dimerization and inhibits interaction with DNA and formation of
LLPS, while being necessary for active gene transcription. The
apparently conflicting effects of phosphorylation in promoting
gene transcription24, while reducing LLPS in chromatin32, may
suggest that phosphorylated and unphosphorylated BRD4 form
different molecular associations in LLPS. The transient polyvalent
self-associations of unphosphorylated BRD4 LLPS32 contrast with
the stable dimeric interaction of phosphorylated BRD4. The level
of BRD4 phosphorylation may therefore modulate the structural
and ligand binding properties of the BRD4 LLPS to decrease
DNA binding and enhance interaction with transcriptional
Fig. 6 biBET inhibitors induce BRD4 compaction in vitro and in cells. a Effects of increasing concentration of bivalent compounds versus monovalent
I-BET on the interaction between H3 and BRD4 full length or H3 and BRD41–722 measured by NanoBRET. The mean with SD is reported (n= 4 independent
experiments). b Effects of increasing concentrations of bivalent compounds versus monovalent I-BET on BRD41–722 dimerization. The mean with SD is
reported (n=4 independent experiments). c Effects of the addition of biBET inhibitors on the SEC-MALS elution profiles of BRD41–722 produced in insect
cells (phosphorylated) or d produced in insect cells and treated with λ-phosphatase (dephosphorylated). e Model of BRD4 dimerization driven by CK2
phosphorylation. The isoform C of BRD4, used in the study, is depicted. The NPS and CPS regions are represented as red boxes, the coiled-coil region (aa
506-530) is drawn as a wavy line and the phosphorylation-dependent dimerization domain (PDD) comprising NPS, the coiled-coil region and BID, is
highlighted. The proposed conformation of the dimer is head to tail. Compounds are labeled as follows: I-BET red-circle and line; compound six blue square
and line, compound seven green triangle and line, AZD5153 purple inverted triangle and line, compound 10 orange rhombus and line, DMSO control
grey line.
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complexes, while maintaining interaction with acetylated histones
so that when levels of BRD4 phosphorylation rise above a certain
threshold transcription is triggered at gene loci. This suggests that
phosphorylation and dephosphorylation of BRD4 mediates a
dynamic interplay between DNA binding and dimerization to
regulate transcription.
In the last few years, potent and selective inhibitors targeting
the bromodomains of BET proteins have been developed38,39.
The biochemical and structural assays guiding drug design were
mainly based on truncated constructs comprising BD1, BD2 or
BD1-BD2. In BRD4, the finding that regions downstream of BD2
are involved in phospho-regulation of binding to chromatin and
other interacting partners27,29, and in the development of resis-
tance against iBETs28, underlines the need to employ more
physiologically relevant constructs in biochemical and biophysical
studies to better resemble the native context.
Our NanoBRET experiments in HCT116 cells and SEC-MALS
data indicated a conformational change of BRD41–722 upon
addition of bivalent compounds, which target two bromodomains
simultaneously (Fig. 6). We previously showed that biBETs afford
an increase in potency in cell assays over corresponding mono-
dentate inhibitors of up to four orders of magnitude and that
biBETs are capable of engaging both bromodomains in BD1-BD2
constructs simultaneously23. Here, we confirm that biBETs are
able to induce a protein rearrangement of BRD4, independently
of its oligomeric state.
Our results show that phospho-dependent BRD4 dimerization
brings BD2 and ET domains into proximity, suggesting that a
bivalent strategy, similar to that of biBETs, might be a viable
approach to simultaneously target BD and ET domains, thus
influencing coregulator interactions and perhaps resulting in
inhibitors with different pharmacological and safety profiles. The
NMR-derived structure of the ET domain was recently solved
with a peptide ligand suggesting the ET domain as a target for
small-molecules inhibitors40. Bivalent strategies may be of wider
value in targeting phase-separated condensates where the high
concentrations of multi-domain proteins with flexible intrinsi-
cally disordered regions may provide enhanced avidity for
binding.
In conclusion, our study provides an important contribution to
the understanding of the molecular details of BRD4 function, and
a refined model for BRD4 activation and inhibition that can be
employed in drug discovery for the development of more specific,
effective and safe therapies and suggests a general strategy for
therapeutic targeting of epigenetics by exploiting avidity to
achieve potency and selectivity in binding.
Materials and methods
Recombinant protein production. Variants of human BRD4 were generated by
gene synthesis (GeneArt, Life Technologies) with an N-terminal 6xHistidine
(6xHis) tag or 6xHis-Halo tag followed by tobacco etch virus (TEV) protease site.
For bacterial expression, constructs were subsequently cloned into a pET28b vector
and transformed into Escherichia coli (E. coli) Bl21 Gold (DE3) strain (Novagen).
Protein expression was induced at 0.6–0.8 OD600 with 0.1 mM IPTG and sustained
overnight at 18 °C. For insect cell expression, constructs were cloned into a
pFastBac1 and bacmid DNA was produced in E. coli DH10 Bac cells. Recombinant
baculoviruses were generated in Sf21 cells (Thermofisher) and protein expression
was conducted at 27 °C for 48 h. Cells were lysed using a Constant Systems cell
disruptor in 50 mM Hepes pH 8.0, 300 mM NaCl, 5 mM Tris(2-carboxyethyl)
phosphine hydrochloride (TCEP), 10 mM Imidazole, 10% Glycerol, 1x Complete
EDTA-free protease inhibitors (Roche) and benzonase nuclease (5 u/ml, Sigma).
For insect cell samples, 1x Halt phosphatase inhibitors (Thermo Fisher Scientific)
were additionally added. Cells were clarified by centrifugation at 43260 rcf for
45 min at 4 °C and incubated with Ni-NTA agarose (QIAGEN) overnight at 4 °C.
Bound proteins were washed with lysis buffer supplemented with NaCl to 1M and
eluted in 50 mM Hepes pH 8.0, 50 mM NaCl, 1 mM TCEP, 300 mM Imidazole, 5%
Glycerol. BRD4 was further purified by ion-exchange chromatography using
Resource columns (GE Healthcare) and a 50-500 mM NaCl linear gradient. A final
purification step by SEC was performed using HiLoad Superdex 200 16/600
column (GE Healthcare) in storage buffer (10 mM Tris pH 8.6, 500 mM NaCl, and
1 TCEP).
CK2α1–335 expression construct was synthesized untagged by GeneArt (Life
Technologies) and cloned into a pET28b vector. Protein expression was conducted
as described for BRD4 bacterial expression. Cells were lysed using a Constant
Systems cell disruptor in 25 mM Tris pH 8.5, 300 mM NaCl, 1 mM TCEP, 1x
Complete EDTA-free protease inhibitors (Roche), and benzonase nuclease (5 u/ml,
Sigma). After centrifuging at 43260 rcf for 45 min at 4 °C, the supernatant was
loaded onto a HiTrap Heparin column (GE Healthcare) and eluted with a 0.3–1M
NaCl linear gradient. Fractions containing CK2α1–335 were diluted to a final NaCl
concentration of 100 mM, loaded onto Resource Q (GE Healthcare) and eluted
with a 100–500 mM NaCl linear gradient. Protein fractions were further purified by
SEC with a HiLoad 16/600 Superdex 75 column (GE Healthcare) in 25 mM Tris
pH 8.5, 500 mM NaCl, 1 mM DTT.
In vitro phosphorylation of BRD4 by CK2. During purification, ion-exchange
fractions containing bacterial BRD4 constructs were pulled together and diluted 1:2
into a final reaction including 50 mM Tris pH 7.5, 10 mM MgCl2, 0.1 mM EDTA,
2 mM DTT, 500 µM ATP, 0.5x Complete EDTA-free protease inhibitors (Roche),
0.5x Halt phosphatase inhibitors (Thermo Fisher Scientific) and CK2α1–335 with a
protein:kinase ratio of 15:1 (w:w). The reaction was incubated overnight at 4 °C,
supplemented with 500 µM ATP and further incubated at 30 °C for 2 h. Phos-
phorylated BRD4 constructs were isolated by anion-exchange with a Resource Q
column and further subjected to SEC using Superdex 200 10/300 GL column in
storage buffer (10 mM Tris pH 8.6, 500 mM NaCl and 1 TCEP).
Intact mass spectrometry analysis. Samples were desalted and concentrated with
0.5 ml Millipore Amicon Ultra cut-off filters (UFC505008, UFC503024) in a
refrigerated centrifuge (4 °C). The mobile phase used for gradient elution consisted
of (A) 0.1% formic acid (Fluka 5630-10XML-F) in water (JT Baker, 4218-02) and
(B) 0.1% formic acid in Acetonitrile (JT Baker, JT9017-2). The LC/MS system used
a Shimadzu Prominence HPLC with a Agilent C8 column (Poroshell StableBond
300 C8, 2.1 × 75 mm, 5 µm) at 500 ul/min flow rate with a gradient consisting of
1 min at 20% B, then ramp to 95% B over 4 min, then hold for 1 min at 95% B
before returning to 20% B. Mass spectra (LC/MS) were acquired on a Sciex 5600
TripleTOF+ mass spectrometer (Foster City, CA) using Analyst 1.6 software
(Foster City, CA). Source temperature was 450 C, spray voltage (ISVF) was 5500 V,
curtain gas was 30, GS1= 60, GS2= 70, and data were acquired over
1000–4000 Da mass range. Protein peak reconstruction (charge state deconvolu-
tion) used the BioToolKit MicroApp v2.2 in the Sciex PeakView 2.2 software.
ADPglo assay. Luminescent ADP detection assay was performed using the
ADPglo kit (Promega). Eleven serial two-fold dilutions of BRD41–722 starting from
85 µM were prepared in assay buffer (50 mM Tris pH 7.5, 10 mM MgCl2, 0.1 mM
EDTA, 2 mM TCEP). For the reaction, 2 µl of each BRD4 dilution was mixed with
0.6 µM CK2α1–335 and 0.2 mM Ultra Pure ATP (Promega) in a final volume of 5 µl
and incubated at RT for 1 h. The ADPglo reagents were added as described in the
ADPglo kit protocol. Luminescence was quantified using the EnVision 2014 plate
reader (Perkin Elmer) and analysed with Prism (GraphPad).
Analytical SEC. For each protein sample, 25 µl at 20 µM was injected into a
Superdex200 PC 3.2/30 column (GE Healthcare) equilibrated with 10 mM Tris pH
7.5, 250 mM NaCl, 1 mM TCEP. For high salt analysis, a buffer containing 10 mM
Tris pH 7.5, 1 M NaCl, 1 mM TCEP was used.
Analytical ultracentrifugation. All analytical ultracentrifugation experiments
were performed on either a Beckman XLA or XLI ultracentrifuge. Sedimentation
equilibrium experiments were performed using 6-sector cells with 110 ul of sample
in 10 mM Tris-HCl pH 7.5 with either 250 mM or 1M NaCl. Samples of between
0.1 µM and 15 μM were centrifuged at speeds of 9,000, 13,000, and 20,000 rpm for
15-hours where equilibrium was attained and scanned using wavelengths of
230 nm and 280 nm. Data was selected based on appropriate absorbance and speed
and analysed using HeteroAnalysis developed by James Cole and Jeffrey Lary,
Version 1.1.57 using a single species model and floating the buoyant molecular
weight. Sedimentation velocity was used to ascertain the sedimentation coefficients
in both 250 mM NaCl and 1M NaCl. Sedimentation velocity experiments were
performed using a An50Ti rotor and standard 2-sector Epon centerpieces and
quartz windows. Samples were diluted prior to loading in the centrifuge and
referenced with the corresponding buffer. The ultracentrifuge was run at a speed of
45,000 rpm collecting scans at 280 nm until full sedimentation had been reached.
Samples were analysed using the program Sedfit developed by Peter Schuck41.
Sedimentation coefficient distributions were corrected to standard conditions using
the buffer density and viscosity correction. The partial specific volume was set to
0.73 cm3/g.
SEC-MALS. In order to characterize BRD4 oligomeric state, size-exclusion chro-
matography coupled to multi-angle light scattering was used to ascertain the
weight-average mass of particles eluting from a gel filtration column using a Wyatt
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Helios II 18-angle light-scattering instrument coupled to a T-Rex differential
refractometer and a QELS in-line dynamic light-scattering instrument. A Superose
6 (GE-life sciences) 24-ml gel filtration column was used to separate proteins
according to their molecular weight. The column was equilibrated in 10 mM Tris-
HCl pH 7.5 with either 250 mM or 1M NaCl and samples were loaded using a flow
rate of 0.75 ml/minute on a Bio-Rad NGC FPLC instrument. The mass and
polydispersity of the samples eluting from the column was performed using the
angular dependence of the scattered light from the sample in the light-scattering
detector, and the concentration from the differential refractive index detector. A
value of 0.183 ml/g was used for the dn/dc value.
In order to characterize the effects of bivalent BET inhibitors on BRD4, SEC-
MALS was performed on a Malvern Omnisec Resolve/Reveal system
compromising of LALS, RALS, UV, RI, and a viscometer. Insect cell-expressed
BRD4 (1-722), before and after dephosphorylation at a concentration of 2 mg/ml
(25 μM) was mixed with compounds to a final concentration of 25 μM, 1% DMSO
and incubated on ice for 1 h. For each sample, 10 µl was injected into a
Superdex200 increase 3.2/300 column (GE Healthcare) equilibrated with 10 mM
Tris pH 8, 300 mM NaCl, 2 mM TCEP.
Hydrogen-deuterium exchange mass spectrometry (HDX-MS). HDX-MS
experiments were performed in triplicates for each time point. Protein stock
solution concentrations were adjusted to 70 µM using BRD4 storage buffer (10 mM
Tris pH 8.6, 500 mM NaCl, and 1 TCEP) and further diluted to 15 µM with
dilution buffer (20 mM Tris pH 7.0, 150 mM NaCl, 1 mM TCEP) in order to reach
a final NaCl concentration of 230 mM and a final pH of 7.5. Hydrogen-deuterium
exchange reactions were conducted using the automated LEAP H/D-X PAL system
(LEAP Technologies) as follows: 5 μl of BRD4 constructs at 15 µM were added to
50 µl D2O labeling buffer (20 mM Tris pD 7.5, 150 mM NaCl, 1 mM TCEP, and
94.8% D2O) at 20 °C. The hydrogen-deuterium exchange reactions were quenched
at different time points (0.5, 50, 180 min) by transferring 50 μl of the mixture to
50 μl of pre-chilled quench solution (4 M Urea, 1.8% formic acid, pH 2.5) at 0 °C
and 80 μl of the reaction+quenched solution was then injected into a Acquity
UPLC M-class system (loop volume 50 μl)(Waters). Undeuterated sample (time
point 0) was prepared identically, except substituting D2O labeling buffer with a
H2O labeling buffer. For the shortest time point (0.3 sec), the reaction was
manually prepared, by incubating 5 μl of BRD4 constructs at 15 µM with 50 μl D2O
labeling buffer on ice for 3 s. After mixing 50 μl of reaction with 50 μl ice-cold
quench solution, the sample was immediately snap-frozen in liquid nitrogen and
kept at −80 °C until LC/MS analysis, prior to which, it was quickly thawed and
injected into the UPLC system.
In order to measure deuterium incorporation the quenched samples were
injected into an immobilized pepsin column (Enzymate BEH-Pepsin column,
Waters) for 3 min at 20 °C with a flow rate of 100 µl/min of 95% buffer A (0.1 %
formic acid in H2O) and 5% buffer B (0.1% formic acid in acetonitrile). Peptides
were trapped on a VanGuard C18 Pre-column (Waters) and subsequently
separated on a C18 reverse phase analytical column (100 mm × 1mm, Waters) at
0.5 °C, using a gradient of 10–40% buffer B over 11 min at a flow rate of 40 μl/min.
Eluents were analysed on a Synapt G2-Si (Waters), acquiring over a mass range of
50–2000m/z, using an ESI source operated at 200 °C and a spray voltage of 3 kV. In
order to avoid carryover, a blank was run after each sample by injecting buffer A,
and two washes of the pepsin column were performed after each run with 1x
Quench buffer + 20% methanol.
For peptide identification, the data for the undeuterated sample were acquired
in MSE mode and analysed with ProteinLynx Global Server (PLGS, Waters). For all
samples and all-time points, peptides with at least 5000 intensity, 0.3 products per
amino acids, 1 consecutive product, and a PLGS score of 6.4, were analysed using
DynamX (Waters). The isotope peaks were identified automatically by the software
and then manually validated in order to exclude ambiguous annotation or
overlapping peptides. For every time point of every peptide, the deuterium uptake
is calculated by subtracting the centroid of the peptide isotopic distribution at time
0 from the centroid of the peptide isotopic distribution at each time point. For each
time point, only averages of deuterium uptake difference greater than 0.5 Da and
higher than 2.3x standard deviation were considered significant. The deuterium
incorporation per residue was calculated by taking into account the average










resj : mean deuterium uptake difference of residue j.
N : number of overlapping peptides containing residue j.
pepi : deuterium uptake difference of peptide i, containing residue j.
amidei : number of exchanging residues of peptide i.
All results are presented as relative levels of deuterium incorporation where no
correction for back exchange is applied. Peptides showing EX1 kinetics were
analyzed with HX-Express242.
Cross-linking mass spectrometry (XL-MS). Purified solutions of both unpho-
sphorylated and CK2 in vitro phosphorylated BRD41–722 were diluted to a con-
centration of 0.082 mg/ml in 20 mM HEPES pH 7.8, 250 mM NaCl, and 1 mM
DTT and cross-linked using a homobifunctional, isotopically-coded N-
HydroxySuccinimide (NHS) ester BS3 (H12/D12) purchased from Creative
Moleucles (Canada) at a concentration of 0.058 mg/ml.
The cross-linked samples were fractionated by size-exclusion chromatography
on a Superose 6 Increase 3.2/300 column with 20 mM HEPES pH 7.8, 250 mM
NaCl and 1 mM DTT at a flow-rate of 50 µl/min and fraction collected every
minute. Each fraction collected at elution volumes between 1.7 and 2.2 ml was
checked by SDS-PAGE and the amount of both dimer and monomer evaluated.
Fractions eluting between 2 and 2.2 ml, enriched in monomers, were combined for
both unphosphorylated and CK2 in vitro phosphorylated BRD41–722 samples.
Dimers were mainly observed in fractions between 1.7 and 1.85 ml and were
combined for CK2 in vitro phosphorylated BRD41–722.
Cross-linked samples were freeze-dried and resuspended in NH4HCO3 50mM
to a protein concentration of 1 mg/ml. The samples were reduced and alkylated
with DTT 10 mM and iodoacetamide 50 mM, respectively. Proteins were
sequentially digested with trypsin and Glu-C. Both the enzymes were added at an
enzyme-to-substrate ratio of 1:20 and the reaction incubated overnight at 37 °C.
The reaction was started by trypsin followed by Glu-C addition after 4 h. After
digestion, the samples were acidified with formic acid and the peptides were
fractionated by peptide size-exclusion chromatography.
Digests were then fractionated by peptide-level size-exclusion chromatography
using a Superdex Peptide 3.2/300 (GE Healthcare) with a 30% Acetonitrile 0.1%
TFA mobile phase at a flow rate of 50ul/min. Fractions were collected every 2 min
from the elution volume 1.0 ml to 1.7 ml. Before LC-MS analysis fractions were
dried and resuspended in 2% Acetonitrile and 2% formic acid.
The digests were analysed by nano-scale capillary LC-MS/MS using an Ultimate
U3000 HPLC (ThermoScientific Dionex, San Jose, USA) to deliver a flow of
approximately 300 nL/min. A C18 Acclaim PepMap100 5 µm, 100 µm × 20mm
nanoViper (ThermoScientific Dionex, San Jose, USA), trapped the peptides prior to
separation on a C18 Acclaim PepMap100 3 µm, 75 µm × 250 mm nanoViper
(ThermoScientific Dionex, San Jose, USA). Peptides were eluted with a gradient of
acetonitrile. The analytical column outlet was directly interfaced via a nano-flow
electrospray ionization source, with a hybrid dual pressure linear ion trap mass
spectrometer (Orbitrap Velos, ThermoScientific, San Jose, USA). MS data were
acquired in data-dependent mode. High-resolution full scans (R= 30,000, m/z
300-2000) were recorded in the Orbitrap. The ions correposnding to the 10 most
intense MS peaks were sequentially selected and CID activated (normalized
collisional energy 35). MS/MS scans were acquired in the linear ion trap.
Xcalibur raw files were converted into the MGF format using MSConvert
(Proteowizard)43 and used directly as input files for Stavrox44. Searches were
performed against the protein sequence and a set of randomized decoy sequences
generated by the software. The following parameters were set for the searches:
maximum number of missed cleavages 3; minimum and maximum peptide length
of 5 and 10 amino acids, respectively; variable modifications: carbamidomethyl-Cys
(mass shift 57.02146 Da), Met-oxidation (mass shift 15.99491 Da); cross-linker
composition: C8H10O2 for H12-BS3 and C8H10O2D12-H12 for D12-BS3; residue
pairs considered for cross-linking reaction: K-K, K-S, K-Y, K-T; MS1 tolerance 5
ppm, MS2 tolerance 0.5 Da; false discovery rate cut-off: 5%. The MS/MS spectra of
identified cross-links were manually inspected and validated.
NanoBRET. Plasmids for the NanoBRET experiments were constructed by sub-
cloning BRD41–722 constructs into N-terminally tagged NanoLuc-TEV (pFN31K)
or C-terminally tagged Halo-TEV (pFC14K) vectors (Promega). Untagged
BRD41–722 construct was prepared by amplifying BRD41–722 with STOP codon
and cloning it into pFC14K vector. Halo-TEV-H3.1 in pFN21A was obtained from
Promega. HCT116 human colorectal carcinoma cells (ATCC; CCL-1573) were
cultured in McCoy’s 5 A medium containing 2 mM glutamine and 10% FCS. For
transfection, 8 × 105 cells were seeded into a 6-well culture plate and allowed to
attach for 4 h. A mixture containing 2 µg of Halo-tagged protein vector, 0.02 µg of
NanoLuc-tagged protein vector, and 8 µl Fugene HD (Promega) was added to each
well. For the titration experiment, 4 × 105 cells were seeded into a 12-well culture
plate and allowed to attach for 4 h. Three-fold serial dilutions of Halo-tagged
BRD41–722 vector were prepared in 1 µg/µl transfection carrier DNA (herring
sperm DNA, Sigma) starting from 1 µg/µl. One µl of each dilution was combined
with 10 ng of NanoLuc-tagged protein vector and 4 µl Fugene HD and added to
each well. Transfections for the competition experiment were performed as for the
titration experiment with the following differences: 8x serial 3-fold dilutions of
untagged BRD41–722 vector were prepared in 1 µg/µl transfection carrier DNA
(herring sperm DNA, Sigma) starting from 1 µg/µl; 1 µl of each dilution was
combined with 10 ng of Halo-tagged BRD41–722 vector, 1 ng of NanoLuc-tagged
protein vector, and 4 µl Fugene HD, and added to each well of the 12-well culture
plate. In all cases, proteins were allowed to express at 37 °C in 5% CO2 for
approximately 20 h. Cells were then harvested and resuspended in OptiMeM (Life
Technologies) with 4% fetal calf serum at 2 × 105 cells/ml in presence of 100 nM
Halo-Tag 618 Ligand (Promega) or 0.1% DMSO (control). Forty microliter (8000
cells) were transferred into a white, flat-bottomed, tissue-culture-treated 384-well
plate (Greiner). When testing compounds, varying amounts solubilized in DMSO
were previously added to the plate using an automated D300 Digital Dispenser
(TECAN), normalizing the final DMSO concentration to a maximum of 0.3%.
Plates were incubated for approximately 18 h at 37 °C in the presence of 5% CO2.
NanoBRET Nano-Glo Substrate (Promega) was added to both control and
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experimental samples at a final concentration of 10 μM. Plates were read within
10 min using a Pherastar FS multimode plate reader (BMG Labtech) equipped with
a NanoBRET filter module (excitation 450 nm, emission 610nm-LP). The results
were reported as milliBRET units (acceptor emission value 610 nm/donor emission
value 450 nm) × 1000). Data were fitted with Prism (GraphPad), using the fol-
lowing equations: one site-total non-linear equation for the titration experiment
[Y= Bmax*X/(Kd+X)+NS*X, where Bmax is the maximum specific binding, Kd
is the equilibrium binding constant, NS is the slope of nonspecific binding];
variable four-parameter curve fit for testing effects of the compounds on BRD4
dimerization or BRD4-H3 interaction [Y=Bottom+ (Top-Bottom)/
(1+ 10((LogEC50-X)*HillSlope))]; variable four-parameter curve fit for testing the
effects of the compounds on the BRD4-H3 interaction and for the BRD4 com-
petition experiment [Y=Bottom+ (Top-Bottom)/(1+ 10((LogIC50-X)*HillSlope))].
Statistics and reproducibility. The details about experimental design and statis-
tics used in different data analyses performed in this study are given in the
respective sections of results and methods. For the HDX-MS experiments using
BRD41–530, BRD41–579, and BRD41–722, different biological samples were analyzed
comprising protein from different purification batches.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
All relevant data are within the paper and its Supplementary Information file. The source
data of the HDX-MS, XL-MS and NanoBRET experiments are provided as Source Data
files. Uncropped SDS-PAGE gel images are provided in Supplementary Figure. Source
data for the graphs and charts in the main figures is available as Supplementary Data 3.
Additional data that support the findings of this study are available from the
corresponding author on request.
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